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Abstract
Aim: The aim was to assess the health utility of lung metastasectomy in the treatment of 
patients with colorectal cancer (CRC) using the EQ-5D-3L questionnaire.
Methods: Multidisciplinary CRC teams at 14 sites recruited patients to a two-arm ran-
domized controlled trial—Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC). 
Remote randomization was used, stratified by site and with minimization for seven 
known confounders. Participants completed the EQ-5D-3L questionnaire together with 
other patient reported outcome measures at randomization and then again at 3, 6, 12 and 
24 months. These were returned by post to the coordinating centre.
Results: Between December 2010 and December 2016, 93 participants were rand-
omized, 91 of whom returned questionnaires. Survival and patient reported quality of 
life have been published previously, revealing no significant differences between the 
trial arms. Described here are patient reported data from the five dimensions of the EQ-
5D-3L and the visual analogue scale (VAS) health state. No significant difference was 
seen at any time point. The estimated difference between control and metastasectomy 
patients was −0.23 (95% CI –0.113, 0.066) for the composite 0 to 1 index scale based on 
the descriptive system and 0.123 (95% CI –7.24, 7.49) for the 0 to 100 VAS scale.
Conclusions: Following lung metastasectomy for CRC, no benefit was demonstrated for 
health utility, which alongside a lack of a survival or quality of life benefit calls into ques-
tion the widespread use of the procedure.
K E Y W O R D S
lung metastasectomy, colorectal cancer, randomized controlled trial
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1  |  INTRODUC TION
The results of the Pulmonary Metastasectomy in Colorectal Cancer 
(PulMiCC) randomized controlled trial (RCT) showed no survival ben-
efit from lung metastasectomy for colorectal cancer (CRC). Hence any 
survival benefit that might be revealed by a much larger trial is likely 
to be far smaller than has generally been supposed [1]. Quality of life 
(QoL) in PulMiCC included four patient reported outcome measures: 
the general and anaemia scale of the Functional Assessment of Cancer 
Therapy (FACT-G-An) [2], selected items from the lung cancer brief 
symptom index [3] and the short form of the Spielberger State/Trait 
Anxiety Inventory (STAI) [4]. These were chosen as the most relevant 
assessments for a thoracic oncological surgical intervention. No signifi-
cant differences were found between the control and metastasectomy 
arms of the trial for any QoL outcomes and minimally important differ-
ences in these measures were largely ruled out [5].
In the absence of a demonstrable benefit in either survival or 
QoL in PulMiCC, we examined the health utility of surgical removal 
of CRC lung metastases. Here we report analysis of the data from 
the EQ-5D-3L questionnaire. This is a standardized health utility 
questionnaire, developed by the EuroQol Group that provides a sim-
ple, generic measure of health for clinical and economic appraisal [6]. 
It is most often used in health economics studies to generate quality 
adjusted life years. The PulMiCC EQ-5D-3L results reported here 
complement the trial survival data [1] (Figure 1) and will contribute 
to a future health economics evaluation.
What does this paper add to the literature?
Surgical excision of lung metastases from colorectal cancer 
provides no health utility benefit among 91 patients in the 
PulMiCC randomized controlled trial.
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TA B L E  1  Trial sites and number of patients returning any forms
Site Returns
Serbia, Institute for Lung Diseases of Vojvodina 28
Sheffield, Northern General Hospital 16
Basildon, Basildon Hospital 8
Middlesbrough, James Cook Hospital 7
Liverpool, Heart and Chest Hospital 7
Burton, Queen's Hospital 6
Bristol, Royal Infirmary 5
Manchester, Christie Hospital 4
London, Royal Free Hospital 3
Plymouth, Derriford Hospital 2
Wolverhampton, New Cross Hospital 2
London, Royal Brompton Hospital 2
Leicester, Glenfield Hospital 1
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2  |  METHODS
As full details of the RCT have been previously reported [1,5] the trial 
design is provided only briefly. PulMiCC had two stages of consent. 
First, following written informed consent, patients with lung metas-
tases were registered for assessment. Those subsequently found to 
be eligible for metastasectomy, according to current practice, were 
invited to consent to randomization, which was either to continued 
standard care (control) or metastasectomy. Sussex Health Outcomes 
Research and Education in Cancer (SHORE-C), University of Sussex, 
administered and coordinated all patient reported outcome measures.
The full trial protocol can be accessed online: https://www.ucl.
ac.uk/clini cal-opera tiona l-resea rch-unit/sites/ clini cal-opera tiona 
l-resea rch-unit/files/ pulmi cc_proto col_decem ber_2015.pdf. In arm 
1, Control, patients were managed without metastasectomy, ra-
diotherapy or image guided thermal ablation. In arm 2, Pulmonary 
Metastasectomy, the surgical approach (videothoracoscopy or open 
thoracotomy) was at the discretion of the surgeon.
2.1  |  Participants
Patients were eligible for inclusion if they had undergone resection 
of primary CRC with a prospect of cure and had pulmonary metas-
tasis confirmed at a multidisciplinary team meeting. The discovery 
of the metastases could be synchronous or metachronous. In line 
with usual practice, there had to be no clinical indications of active 
CRC other than the known lung metastases. Prior liver resection for 
metastases did not preclude entry to the trial.
Following consent to randomization, patients were given the EQ-
5D-3L questionnaire [7] at baseline. Subsequently, it was adminis-
tered at 3, 6, 12 and 24 months. The questionnaire asks patients 
to indicate on a visual analogue scale (VAS) their own health state 
‘today’, between zero, worst imaginable health state, and 100, best 
imaginable health state, and to indicate their well-being in five dimen-
sions (mobility, self-care, usual activity, pain and discomfort, anxiety 
and depression) as 1, 2 or 3, the three levels denoting no, some and 
extreme problems respectively. Country-specific composite indices, 
TA B L E  2  Forms were sent at 3, 6, 12 and 24 months
Time point 
(months) 0 3 6 12 24
Data available 
(n = 91 
patientsa )
83 84 82 72 60
Per cent return 91 92 90 79 66
Note: We know from survival data that, by 24 months, the number of 
deaths was 8/46 control, 6/45 metastasectomy.
aNinety-three patients randomized. EQ-5D-3L questionnaire data 
available for n = 91 patients. 
F I G U R E  2  Three-level (3, 2, 1) scores in a traffic light convention, in the five dimensions of well-being in the EuroQol: mobility, self-
care, usual activity, pain and discomfort, anxiety and depression (EQ-5D-3L) at baseline, 3, 6, 12 and 24 months, in the control (left) and 
metastasectomy arms. Each horizontal set of five represents a return from an individual patient. At each time point they are ranked by 
the unadjusted sum of the scores from 5 at the top, to help visibility of the patterns between the arms and over time
Baseline Baseline Met'my 3 months Met'my 6 months Met'my 12 months Met'my 24 months Met'my3 months Controls 6 months Controls 12 months Controls 24 months ControlsControl
MY SC UA PD AD MY SC UA PD AD MY SC UA PD AD MY SC UA PD AD MY SC UA PD AD MY SC UA PD AD MY SC UA PD AD MY SC UA PD AD MY SC UA PD AD MY SC UA PD AD
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on a scale of 0 (worst) to 1 (best), based on the five well-being scores 
were developed. No index was found for Serbia so the UK index was 
calculated for all patients where the majority of trial centres were 
based. Of the randomized patients, 70% were in the UK, and Serbian 
patients were similarly represented in both arms by stratification.
2.2  |  Statistical methods
To analyse the longitudinal EQ-5D-3L health state and index data, 
with adjustment for within-patient correlation, we used linear re-
gression models with estimation using generalized estimating equa-
tions, using an independence working covariance assumption. The 
primary analysis estimated a common effect of metastasectomy 
over the follow-up times of 3, 6, 12 and 24 months, with adjustment 
for follow-up time, but variation of the treatment effect over time 
was examined. The potential impact of losses to follow-up was ex-
amined through fitting singular linear increment models [8].
3  |  RESULTS
Fourteen sites randomized 93 patients (Table 1) 47 to the control 
arm and 46 to metastasectomy. No patient in the control group had a 
metastasectomy as their initial treatment; two had metastasectomy 
later at 14 and 17 months. Two patients declined the assigned me-
tastasectomy. For this analysis, they remain in their assigned groups.
Of 93 randomized patients, one in each arm did not complete 
any EQ-5D-3L questionnaires, leaving 46 control and 45 metasta-
sectomy patients. Fourteen patients died within 24 months: 8/46 of 
controls and 6/45 who had metastasectomy (Table 2).
Summary tabulations of the five EQ-5D-3L well-being compo-
nents are provided in Figure 2. The three levels 1, 2 and 3 are colour 
coded with a traffic light convention, for each of the five dimensions, 
for every patient returning a form. The green ‘no problems’ area di-
minished at a similar rate in controls and metastasectomy patients.
Figure 3 presents the EQ-5D-3L index values, derived from 
the well-being components, over the 24 months of follow-up. The 
estimated effect, comparing metastasectomy with control, was 
−0.023, 95% CI −0.113, 0.066, P = 0.57. There was no evidence that 
the treatment difference varied over time (P = 0.87, three d.f. test). 
Reported minimally important differences for this measure in a UK 
population range from 0.10 to 0.12, suggesting that there is no evi-
dence of any important difference in the index values between the 
randomized groups [9].
Figure 4 presents the EQ-5D-3L health state scores over the 
24 months of follow-up. The estimated effect, comparing metasta-
sectomy with control, was 0.125, 95% CI −7.24, 7.49, P = 0.97. There 
F I G U R E  3  EQ-5D-3L index scores in the two treatment arms: arm 1, control; arm 2, assigned to metastasectomy. Dashed lines are 
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was no evidence that the treatment difference varied over time 
(P = 0.87, three d.f. test).
Figure 5 presents the single dimension, self-reported health 
state on a 1–100 scale with median and interquartile range. It fell in 
both groups at similar rates.
4  |  DISCUSSION
Data reported here from the EQ-5D-3L well-being dimensions and 
health state show no differences between the randomized con-
trol and metastasectomy patients. This outcome is in line with the 
F I G U R E  4  EQ-5D-3L health state scores in the two treatment arms: arm 1, control; arm 2, assigned to metastasectomy. Dashed lines are 
based on generalized estimating equations and solid lines on singular linear models that adjust for drop-out
Number of patients:
2435414043




























F I G U R E  5  The single dimension, self-reported health state on a 1–100 scale with median and interquartile range displayed
100
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finding of no survival or QoL benefit in the PulMiCC RCT [1,5]. 
Lung metastasectomy is sometimes considered for psychological 
benefit but, as previously shown when using a comprehensive as-
sessment of anxiety (STAI), no difference was evident in the anxi-
ety and depression dimension of the EQ-5D-3L. The number of 
patients reporting ‘no problems’ in all the five dimensions of well-
being diminished at a similar rate in controls (left) (Figure 2) and 
metastasectomy patients.
Evaluation of treatment of metastatic disease is a research pri-
ority for the Association of Coloproctology of Great Britain and 
Ireland (ACPGBI) [10] and is one of the targets in management of 
patients with CRC. It is a treatment considered in the Improving 
Management of Patients with Advanced Colorectal Tumours, the 
IMPACT initiative of the ACPGBI [11]. Small effects cannot be ruled 
out by the findings of PulMiCC but they do not show a survival 
or QoL benefit from metastasectomy [5]. The additional study re-
sults reported here make it unlikely that there is a significant gain 
of health utility if patients are subjected to pulmonary metastasec-
tomy. PulMiCC trial results may help to guide further research in 
this important area.
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